On March 5, 2024 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, reported that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 taking place in San Diego, CA, April 5-10 (Press release, Lyell Immunopharma, MAR 5, 2024, View Source [SID1234640783]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One oral and two poster presentations will highlight data from Lyell’s product pipeline and research programs, including:

An oral presentation on Lyell’s rejuvenation technology which has shown the potential to turn back the epigenetic clock to generate more stem-like T cells with reduced epigenetic age and enhanced proliferation ability
A poster presentation of nonclinical data on LYL119, Lyell’s second-generation ROR1-targeted CAR T-cell product candidate
A poster presentation on technology being advanced through a collaboration between Lyell and Outpace to enable tumor-restricted IL-12 activity to enhance solid tumor T cell therapies
Details on the presentations are below.

An oral presentation titled "Rejuvenation of Tumor Infiltrating Lymphocytes: A novel strategy to revitalize TIL antitumor function for cell therapy" will highlight Lyell’s rejuvenation technology which has shown the potential to generate T cells with reduced epigenetic age, more stem-like properties and enhanced proliferation ability. Previously published studies have demonstrated the decline in T-cell function as a person ages. These new nonclinical data show tumor infiltrating lympyocytes (TIL) rejuvenated with Lyell’s technology retain a broad T-cell receptor repertoire and demonstrate sustained proliferation and improved antitumor activities in vivo.

Presentation details:

Session Date/Time: Tuesday Apr 9, 2024 2:30 PM – 4:30 PM
Abstract Number: 6593
Session Category: Immunology
Session Title: New Insights for Therapies Modulating Antitumor T-Cell Responses
New nonclinical data on LYL119, Lyell’s second-generation ROR1-targeted CAR T-cell therapy, will be presented in a poster titled "LYL119, a Preclinical ROR1-Targeted CAR T-Cell Product Incorporating Four Novel Reprogramming Technologies Designed for Effective Cell Therapy for Solid Tumors." LYL119 incorporates four of Lyell’s complementary, stackable T-cell reprogramming technologies and is designed to create potent ROR1-targeted CAR T cells with durable function. In this study, LYL119 demonstrated superior in vivo antitumor efficacy in a mouse xenograft tumor model across a 10-fold dose range, including at very low cell doses. In addition, following repeated rounds of tumor cell killing, LYL119, displayed reduced expression of exhaustion-related gene signatures and retained unique cell subsets characterized by upregulation of memory and effector-associated gene signatures.

Presentation details:

Session Date and Time: Sunday Apr 7, 2024 1:30 PM – 5:00 PM
Abstract Number: 49
Session Category: Immunology
Session Title: Adoptive Cell Therapies 2: CAR-T Cells
A poster presentation titled "Development of Tumor-restricted IL-12 With Antigen-dependent Expression and Localized IL-12 Activity" highlights an innovative tumor-restricted IL-12 (trIL-12) technology that delivers potent IL-12 stimulation at the tumor site while avoiding systemic exposure. IL-12 is an immune-stimulatory cytokine that can induce potent anti-tumor activity, but unregulated systemic delivery of IL-12 has been shown to have a limited therapeutic window. trIL-12 was designed leveraging Outpace’s OUTSMART technology to rapidly auto-inactivate IL-12 after inducible secretion from engineered T cells with the aim of achieving safe, local delivery of IL-12 activity in the tumor microenvironment. trIL-12 is being advanced under a collaboration between Lyell and Outpace with the goal of improving efficacy for T-cell therapies by harnessing the therapeutic potential of IL-12.

Presentation details:

Session Date and Time: Tuesday Apr 9, 2024 9:00 AM – 12:30 PM
Abstract Number: 4067
Session Category: Immunology
Session Title: Immune Modulation with Cytokines